Apatinib combined with S-1 as second-line therapy in advanced gastric cancer

Advanced gastric cancer (AGC) patients are not tolerant to the toxicities of traditional chemotherapy and its second-line therapeutic regimens are limited. The aim of the present study is to evaluate the efficacy and safety of apatinib combined with S-1 as the second-line therapy for AGC patients. P...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Zhi-Yuan, Qin, Rong, Tian, Guang-Yu, Zhang, Zhao, Chen, Meifang, He, Han, Xi, Yan, Wang, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084084/
https://www.ncbi.nlm.nih.gov/pubmed/33907117
http://dx.doi.org/10.1097/MD.0000000000025630

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084084/
https://www.ncbi.nlm.nih.gov/pubmed/33907117
http://dx.doi.org/10.1097/MD.0000000000025630

Ejemplares similares